Clinical and histological response to combination nivolumab and ipilimumab in metastatic renal cell carcinoma.
Proceedings (Baylor University. Medical Center)(2020)
Abstract
Patients with renal cell carcinoma (RCC) often remain asymptomatic until the disease is advanced, with about 25% presenting at an advanced stage. We present a case of metastatic RCC treated with combination ipilimumab and nivolumab with complete radiological and pathological response. Currently, combination nivolumab and ipilimumab is a preferred option for intermediate- and poor-risk patients with clear cell stage IV RCC.
MoreTranslated text
Key words
Complete response,immunotherapy,nivolumab and ipilimumab,renal cell carcinoma
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined